QUEBEC – August 8, 2006 - Advitech today announced the preliminary results on Atopic Dermatitis (AD), a third potential application originating from its XP-828L platform. The peptidic extract demonstrated significant results in reducing in vitro and in vivo IL-4 production by immune cells. The general consensus is that AD is an immune-mediated skin disease characterized by a predominance of IL-4 leading to IgE production resulting in inflammation. Further studies are in progress in order to confirm the efficacy of the product against AD. Atopic dermatitis, or eczema, is a chronic skin disorder characterized by pruritus, dry skin, and excoriation, which may be localized to a few patches or involve large portions of the body. It is a common disease affecting approximately 6% of the general population, particularly children. In the United States alone, it is estimated that more than 15 million individuals are afflicted with this disorder.
This confirms the Company’s objective to commercially develop additional applications originating from its XP-828L research platform. Originating from this platform, the Company previously announced positive pre-clinical and clinical results on psoriasis and positive pre-clinical results on irritable bowel disease. The psoriasis application is presently commercialized under the DermylexTM brand.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY TO PUBLISH A SECOND SCIENTIFIC ARTICLE ON DERMYLEX ™
The Journal of Cutaneous Medicine and Surgery, a peer reviewed journal, has confirmed that it will publish in the coming months a second scientific article on Dermylex™ to comment on the results of the 2005 double blind placebo controlled clinical study released in July 2005.
Advitech is a life sciences and technology company specializing in the development of clinically tested bioactive ingredients for chronic immune-mediated inflammatory diseases (IMID), such as psoriasis and inflammatory bowel diseases. Advitech’s common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54,799,818.
Dermylex™ is Advitech’s orally administered product for mild to moderate plaque psoriasis made from a bioactive ingredient with proven clinical efficacy. On July 5, 2005, the Company reported positive results from its Phase II clinical trial for treating mild to moderate psoriasis. The 112-day, multi-center, double blind, placebo-controlled study, involving 84 patients, confirmed the efficacy and excellent safety profile of Dermylex™ for treating mild to moderate psoriasis. For more information please visit www.dermylex.ca
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ significantly from those projected herein.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
For further information, please contact: